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Abstract
In clinical practice, the glomerular filtration rate (GFR) is often determined with serum creatinine. However, studies have shown 
cystatin C to be a better parameter for the diagnosis of impaired renal function. We compared GFR estimated by plasma cys-
tatin C with GFR estimated by serum creatinine in a sample of 50 pediatric renal transplant recipients and 24 healthy children. 
The correlation between GFR estimated by serum creatinine and by cystatin C was significant (r = 0.75; P < 0.001, Pearson’s 
correlation); however, in pediatric kidney transplant recipients, the GFR was 6.7 mL/min lower when determined using cys-
tatin C rather than serum creatinine. Moreover, using GFR estimated by cystatin C we found that 42% of the pediatric kidney 
transplant recipients had an estimated GFR <60 mL·min-1·1.73 (m2)-1, whereas when GFR was estimated by the serum crea-
tinine formula only 16% of the children had values below this cutoff point indicative of chronic kidney disease (P < 0.001). We 
conclude that, in pediatric kidney transplant recipients, estimation of GFR yields lower values when cystatin C is used rather 
than serum creatinine.
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Monitoring of kidney graft function is mandatory for the 
detection of acute or chronic rejection and for the accom-
panying immunosuppressive therapies (1,2). Glomerular 
filtration rate (GFR) is considered to be the best marker 
of renal function, and serum creatinine is the biochemical 
parameter most commonly used to estimate GFR in routine 
practice. However, there are some shortcomings regarding 
the use of this parameter. Factors such as lean muscle mass 
and protein intake can influence serum creatinine, leading 
to an inaccurate estimation of GFR (2-4). 
Cystatin C (CysC) is a nonglycosylated protein belong-
ing to the cysteine protease inhibitors and is produced at 
a constant rate in all nucleated cells, removed from blood 
plasma by glomerular filtration and reabsorbed by the renal 
tubules (5,6). Moreover, its concentration is not influenced 
by diet, age, gender, lean muscle mass, and/or infections 
(7,8). Studies have suggested that CysC is a better marker 
of GFR than serum creatinine (Scr) (9-11). Nonetheless, 
there are contradictory reports about the value of CysC as 
a marker for GFR, particularly in pediatric renal transplan-
tation (12,13). Several studies have been conducted to 
develop procedures for the estimate of GFR from CysC and 
the use of CysC levels as a GFR measure is widespread 
in clinical practice. Some predictive equations have been 
derived from the data of pediatric patients to estimate GFR 
from serum CysC concentration (14). However, only one 
has been validated in a separate cohort of pediatric renal 
transplant recipients (15). Accordingly, the objective of the 
present study was to evaluate and compare the performance 
of plasma CysC and a CysC-based eGFR equation to Scr 
and an Scr-based eGFR equation in a sample of pediatric 
renal transplant recipients, and compare these data with 
those obtained for a sample of children from the general 
population.
Material and Methods
The study was carried out on 50 renal transplant (RTx) 
children (24 boys and 26 girls; mean age, 12.6 ± 0.4 years), 
and who were followed at the Kidney and Hypertension 
Hospital, São Paulo, Brazil. These children were identified 
consecutively in the local ambulatory files among those who 
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were between 12-18 months post-transplantation and had 
stable renal function. Patients were excluded for the follow-
ing reasons: the legally responsible person was unable or 
unwilling to provide informed consent, hospitalization at the 
time of the study, presence of systemic infection requiring 
antibiotic therapy, clinically diagnosed chronic rejection, 
and a recent decline of renal function. Other clinical char-
acteristics of the RTx children and the immunosuppressive 
drugs used at the time of follow-up evaluation are reported in 
Table 1. The control group consisted of 24 healthy children 
(11 boys and 13 girls; mean age, 10.5 ± 0.4 years) living 
in the community in the same region from which the cases 
came. None of the control children had a history of urinary 
tract infection or of renal diseases. In addition, none of the 
children in the study had clinical signs of thyroid dysfunc-
tion. The study was approved by the Ethics Committee of 
the Federal University of São Paulo and written informed 
consent was obtained from one of the parents of each child 
enrolled in the study.
Renal function assays
All children provided a blood sample, which was col-
lected in the morning following an overnight fast. For CysC 
assays, aliquots of heparinized plasma were centrifuged 
at 1500 g for 5 min at 4°C and stored at -80°C. For Scr the 
aliquots were centrifuged at 1500 g for 20 min at 4°C and 
immediately processed in the Clinical Laboratory of São 
Paulo Hospital. CysC was measured with an immunoparticle 
kit (Dako Corp., Denmark) using an immunoturbidimetric 
assay. The range of detection of the assay is 0.3 to 7.5 mg 
per liter, with a reported reference range for young, healthy 
persons of 0.55 to 1.15 mg/L. We estimated GFR based 
on CysC (eGFRcys) using the equation described by Zap-
pitelli et al. (15) as follows: 75.94 / CysC [mg/L]-1.17 x 1.2 (if 
renal transplant). Scr was measured using an automated 
picric acid assay with the Hitachi 717 analyzer according 
to manufacturer instructions in the Clinical Laboratory of 
São Paulo Hospital. The GFR based on Scr (eGFRcr) was 
estimated with the use of the Schwartz formula (16): k x 
height (cm) / Scr [mg/dL]; k = 0.55 in children up to 13 years 
of age. In addition, eGFR was adjusted for a body surface 
area divided by 1.73 m2.
Statistical analysis
All continuous variables were examined for normality 
with the Kolmogorov-Smirnov test. The chi-square test (or 
the Fisher exact test where appropriate) and the McNemar 
symmetry chi-square test were applied for comparison 
of proportions. The Student t-test was used to compare 
mean values of continuous variables between two groups. 
Correlation between continuous variables was determined 
by the Pearson correlation coefficient. Analysis of covari-
ance was used to compare the mean values of CysC and 
eGFRcys between RTx and control groups, with adjustment 
for potential confounding variables. Analyses were also per-
formed by stratifying GFR into <60 and ≥60 mL·min-1·1.73 
(m2)-1 since this level has been recommended as the cutoff 
to define chronic renal failure (17). Data are reported as 
means ± SEM. Statistical tests were two-tailed and the level 
of significance was set at P < 0.05. All data were analyzed 
using the statistical program SPSS 11.0 for Windows.
Results 
The demographic, anthropometric and clinical char-
acteristics of the participants are shown in Tables 1 and 
2. The mean age of the transplant recipients at the time 
of transplantation was 11.2 years (range: 3-16 years) in 
the RTx population and 22.8 years (range: 3-56 years) 
among the donors. Twenty-seven donors were adults and 
23 donors were under 15 years old. The etiology of renal 
failure was uropathy (32%), glomerulonephritis (30%), and 
undetermined or other causes (38%). Live donor grafts 
were used in 34% of patients, adult cadaver grafts in 20% 
and pediatric cadaver grafts in 46%. Arterial hypertension 
was detected in 33 children before renal transplant, with 30 
continuing to be hypertensive after the transplant. 
Concentrations of both CysC and Scr were significantly 
higher in the RTx children compared with the controls 
(Table 2). In addition, eGFRcys and eGFRcr were signifi-
cantly lower in RTx children than in controls (Table 2). In 
an analysis of covariance with adjustment for age and body 
weight, the results remained basically the same: mean 
Table 1. Clinical characteristics of the 50 pediatric renal trans-
plant recipients.
Characteristic
Living donor 17 (34%)
Mean age at transplantation (years) 11.2 ± 0.5
Donor age (years) 22.8 ± 2.3
Acute rejection 9 (18%)
Delayed graft function 8 (16%)
Cold ischemia time (min) 887 ± 92.4
Renal artery stenosis 10 (20%)
Prior time on chronic dialysis (months) 18.5 ± 1.9
Causes of renal disease
Glomerulonephritis 15 (30%)
Uropathy 16 (32%)
Undetermined cause/others 16 (32%)/3(6%)
Immunosuppressive therapy*
Azathioprine 22 (44%)
Mycophenolate mofetil 27 (54%)
Cyclosporine A 9 (18%)
Tacrolimus 43 (86%)
Data are reported as number with percent in parentheses or 
means ± SEM. *All children were taking prednisone at a mean 
dose of 0.10-0.15 mg·kg body weight-1·day-1.
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[95% confidence interval (CI)] for CysC, 1.54 mg/L (1.44 
to 1.63) vs 0.66 mg/L (0.53 to 0.80, P < 0.001) for RTx and 
controls, respectively, and for eGFRcys, 66.3 mL/min (61.0 
to 71.5) vs 125.9 mL/min (118.2 to 133.7, P < 0.001) for 
RTx and controls, respectively. CysC levels were signifi-
cantly correlated with Scr levels (r = 0.74, P < 0.001) and 
eGFRcr (r = -0.80, P < 0.001). None of the anthropometric 
variables correlated significantly with plasma CysC levels 
(age: r = 0.18, P = 0.21, weight: r = 0.20, P = 0.18; height: 
r = 0.16, P = 0.17). 
Divergent results were observed for Scr levels, since 
this marker correlated positively with age (r = 0.41, P < 
0.001), height (r = 0.36, P = 0.002) and weight (r = 0.38, 
P = 0.001). Further analysis of the overall group was per-
formed to test whether CysC and Scr varied by gender, 
and no significant difference between girls and boys was 
noted for either marker (CysC: 1.3 ± 0.09 and 1.2 ± 0.08 
mg/L, P = 0.31, respectively; Scr: 1.0 ± 0.06 and 1.0 ± 
0.058 mg/L, P = 0.87).
Because some recent studies have suggested that 
cyclosporine A (CsA) could promote a decrease in CysC 
levels, we determined the concentration of CysC and crea-
tinine of the children who received this immunosuppressive 
drug. No significant differences were detected in the levels 
of CysC (with CsA: 1.7 ± 0.20 and without CsA: 1.5 ± 0.05) 
or creatinine (with CsA: 1.3 ± 0.19 and without CsA: 1.1 ± 
0.04) between children receiving or not this treatment.
Although GFR estimated by Scr and CysC showed a 
significant correlation (r = 0.75, P < 0.001), in RTx recipi-
ents mean eGFRcys was significantly lower than eGFRcr 
(66.1 ± 2.0 vs 72.8 ± 2.2 mL/min), corresponding to a 
10.1% increase in eGFR when the latter was employed. 
Using the eGFRcys equation, we found that 42% (95%CI: 
28 to 56%; N = 21) of the children had a significant degree 
of impairment of renal function (GFR <60 mL·min-1·1.73 
(m2)-1). On the other hand, when we used the eGFRcr 
we observed that only 16% (95%CI: 6 to 26%; N = 8) of 
the children had GFR values <60 mL·min·1.73 (m2)-1 (P 
< 0.001). Therefore, 62% (13/21) of the children with a 
considerably reduced eGFRcys had a ‘normal’ eGFRcr 
estimated by the Schwartz formula. 
In further analyses, we tested all demographic and 
clinical variables available in relation to eGFRcys (exam-
ined as a continuous or categorical (<60 or ≥60 mL/min) 
variable); however, we were unable to detect statistically 
significant associations between any of the independent 
variables and eGFRcys.
Discussion
Knowledge of GFR is of crucial importance in the man-
agement of pediatric renal transplant patients, in whom an 
accurate measurement of GFR is challenging. Determina-
tion of GFR with high accuracy requires the use of invasive 
techniques based on measuring the plasma clearance rate 
of injected substances that are exclusively excreted via 
glomerular filtration (18). However, these techniques are 
time-consuming, expensive, and not entirely free of risk for 
the patient. Thus, the measurement of endogenous blood 
substances to estimate GFR is a common practice, and Scr 
is the metabolite most commonly used for this purpose, al-
though several drawbacks have been identified (2). Several 
studies have suggested that plasma CysC might be used 
as a GFR marker (9-11). 
The data of the present study show important differ-
ences when using the Zappitelli and the Schwartz equa-
tions (15,16) to assess renal function in renal transplanted 
children. In fact, we observed that 62% of the children 
classified as having an important reduction of renal function 
using eGFRcys were classified as normal when GFR was 
estimated by the Schwartz formula. Using the cut-off point 
of <60 mL·min·1.73 (m2)-1, a remarkably lower percentage 
of RTx children were classified as having values below these 
levels by the Schwartz than by the Zappitelli formula. Based 
on previous studies reporting a greater precision of GFR 
estimation using CysC instead of Scr, our data suggest that 
the former equation may be able to correctly detect more 
patients with impaired renal function. These findings have 
important implications: 1) the classification of reduced renal 
function (and chronic kidney disease) in RTx children varies 
according to the method used to estimate GFR, 2) it seems 
that more patients will be classified as having chronic renal 
disease using a CysC-based than an Scr-based equation, 3) 
if these findings are confirmed, more patients could benefit 
from an early intervention to prevent a further decrease in 
renal function using the eGFRcys equation. The findings of 
this study, taken together with other reports, appear to sup-
port the more promising use of CysC as a possible marker 
Table 2. Renal function tests in the study groups.
Characteristic RTx children 
(N = 50)
Control children 
(N = 24)
Age (years) 12.6 ± 0.4 10.5 ± 0.4*
Weight (kg) 41.3 ± 2.1 32.6 ± 2.4*
Height (cm) 143.7 ± 2.5 137.3 ± 2.7
Creatinine (mg/dL) 1.13 ± 0.05 0.72 ± 0.01*
Range   0.62-2.48  0.60-0.80
eGFRcr (mL·min-1·1.73 (m2)-1) 72.8 ± 2.20 105.3 ± 2.2*
Range    29.9-101.1    91.1-129.3
Cystatin C (mg/L) 1.55 ± 0.05 0.64 ± 0.03*
Range  1.02-2.51  0.47-1.05
eGFRcys (mL·min-1·1.73 (m2)-1) 66.1 ± 2.03 126.3 ± 4.9*
Range  40.2-93.2    75.6-164.8
Data are reported as means ± SEM. RTx = renal transplant; eGFRcr 
= glomerular filtration rate estimated by creatinine; eGFRcys = GFR 
estimated by cystatin C. To convert serum creatinine in mg/dL to 
μmol/L, multiply by 88.4. *P < 0.05 compared to RTx children (Stu-
dent t-test).
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of preclinical or early kidney disease among persons with 
Scr-based eGFR in the ‘normal’ range (≥60 mL·min·1.73 
(m2)-1) but with elevated levels of CysC. Some limitations 
of this study are the relatively small sample size, the lack 
of a direct measure of GFR, and we have not investigated 
predictors of lower eGFRcys.
The present report showed a good correlation between 
CysC and both Scr levels and eGFRcr, but we did not find any 
correlation of CysC with age, gender or other anthropometric 
parameters (7,8). In fact, CysC production in the body is a 
stable process that is not influenced by renal conditions, 
increased protein catabolism, or dietetic factors. Moreover, 
it does not change with age or muscle mass like Scr does 
(19). The effect of age on CysC has been reported. It has 
been demonstrated that circulating levels of CysC reach 
adult values by the 1st year of life and remain constant up 
to the age of 50 years, when it rises significantly due to the 
physiological aging of renal function (14). CysC may have 
limitations as a marker of renal function, since there are 
potential factors other than GFR that have been reported 
to affect serum levels of CysC including older age, male 
gender, smoking, higher weight, higher levels of C-reactive 
protein, and thyroid dysfunction (8,20). Moreover, recent 
studies have reported that CysC levels are affected by 
treatment with high steroid doses (21-24). Higher serum 
CysC levels and underestimation of GFR have been found 
in children on glucocorticoid therapy in the immediate 
post-transplant period and in situations of acute rejection. 
On the other hand, the effect of other immunosuppressive 
medications such as tacrolimus, mycophenolate mofetil or 
azathioprine on CysC concentration has not been reported, 
except for cyclosporine A, which appeared to promote a 
decrease in CysC levels (24). In our study, patients were 
evaluated more than one year after the transplant when 
the steroid dose used was much lower (0.1 mg·kg-1·day-1), 
and was unlikely to have influenced CysC measurements. 
In addition, we did not detect any significant effect of other 
immunosuppressive drugs on CysC levels. 
The recent literature strongly suggests that CysC will 
have a role in assessing renal function in certain groups of 
patients for whom the disadvantages of Scr have become 
apparent. Pediatric renal transplant recipients are a group 
that would greatly benefit from studies better defining 
eGFR equations. In our study, the most frequently used 
Scr-based equation appeared to detect less RTx children 
with a significantly reduced renal function than the CysC-
based equation. If CysC proves to be an earlier marker of 
renal dysfunction in RTx children it will be an important tool 
to improve the management of these children. 
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